Tic Disorders
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria for the case group: (1) Meeting the diagnostic criteria for TD; (2) Having discontinued other psychiatric medications for more than 3 months before treatment; (3) Age greater than 5 years but not exceeding 14 years; (4) Voluntary participation as a subject with written consent provided by the child's guardian and informed assent obtained from children aged 8 years and older. Inclusion Criteria for the Healthy Control Group: (1) No history of any psychiatric disorders including tic disorders (TD) attention deficit hyperactivity disorder (ADHD) autism spectrum disorder depression or anxiety; (2) Passed school entrance physical examination in good health and meeting standard health benchmarks for their age group; (3) Age greater than 5 years but not exceeding 14 years; (4) Willing to participate as a study subject providing fecal samples and engaging in related research procedures; (5) Written informed consent obtained from the child's guardian with additional assent obtained from children aged 8 years and older (using a child-friendly consent form).
Exclusion criteria
Exclusion criteria: Exclusion Criteria for the Case Group: (1) TD caused by chorea athetosis Wilsons disease encephalitis or drug-induced factors; (2) Comorbid neuropsychiatric disorders such as attention deficit hyperactivity disorder (ADHD) autism spectrum disorder depression or anxiety; (3) Presence of intellectual disability; (4) Comorbid primary cardiovascular hepatic renal or hematopoietic system diseases; (5) Presence of organic intestinal diseases or related conditions with gastrointestinal symptoms such as acute/chronic cholecystitis acute/chronic hepatitis acute/chronic pancreatitis hyperthyroidism or diabetes; (6) Long-term use of medications or foods that affect gastrointestinal function. Exclusion Criteria for the Healthy Control Group: (1) Children with a history of psychiatric or neurological disorders; (2) Current use of psychotropic or neurological medications particularly antipsychotics antidepressants or sedatives; (3) Children with developmental delays or disorders in language motor skills social interaction or other areas; (4) Children with primary cardiovascular hepatic renal or hematopoietic system diseases; (5) Presence of organic intestinal diseases or related conditions with gastrointestinal symptoms such as acute/chronic cholecystitis acute/chronic hepatitis acute/chronic pancreatitis hyperthyroidism diabetes or renal insufficiency; (6) Long-term use of medications or foods that affect gastrointestinal function; (7) Children with other diseases or physical conditions that may interfere with the study results and cannot be controlled through intervention.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Yale Global Tic Severity Scale (YGTSS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Fecal Metabolomic Sequencing;Fecal Metagenomic Sequencing;Childhood Anxiety Sensitivity Index(CASI);Clinical Global Impressions(CGI);Quality of Life(QoL); | — |
Countries
China
Contacts
Affiliated Hospital of Nanjing University of Chinese Medicine(Jiangsu Provincial Hospital of Traditional Chinese Medicine)